GlassScriptPhysician profile
Edward D Kim
NPI 1316948029
$52,367.98
in general payments reported to CMS, 2019-2025
55 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,775 · 2021: $18K · 2022: $15K · 2023: $2,903 · 2024: $1,624 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567 · Travel and Lodging: $585 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,567.48 |
| Travel and Lodging | $584.85 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $18,739.05 | 2019-2024 | Xiaflex, Aveed |
| Antares Pharma, INC. | $10,184.77 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Acerus Pharmaceuticals Corporation | $9,340.92 | 2021-2022 | |
| Axonics, INC. | $3,299.57 | 2020-2024 | Axonics, Bulkamid |
| Kowa Pharmaceuticals America, INC. | $2,203.08 | 2022-2023 | Seglentis |
| Coloplast Corp | $2,193.75 | 2019-2025 | Titan |
| Teleflex LLC | $1,868.25 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $486.34 | 2020-2025 | General - Female Sui, General - Erectile Dysfunction, Rezum Generator |
| Janssen Biotech, INC. | $400.24 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $369.33 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $336.20 | 2023-2025 | Gemtesa, Orgovyx |
| Endo USA, INC. | $229.62 | 2024-2025 | Xiaflex, Aveed |
| Blue Earth Diagnostics | $219.12 | 2021-2024 | |
| Urogen Pharma, INC. | $205.96 | 2024-2025 | |
| Olympus America INC. | $176.78 | 2019-2025 | Itind System, Bovie, Oes Cystonephrofiberscope |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.